ArticleBMC gastroenterology2026
Prognostic nutritional index as a predictor of ursodeoxycholic acid response in primary biliary cholangitis: a retrospective study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrimary Biliary Cholangitis (PBC) is an autoimmune hepatic disorder characterized by the progressive destruction of intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) remains the primary treatment modality; however, a subset of patients exhibits non-responsiveness to UDCA therapy. The objective of this study is to investigate the association between the Prognostic Nutritional Index (PNI) and UDCA treatment non-responsiveness in individuals diagnosed with PBC.
methodsThis retrospective study encompassed PBC patients who received UDCA therapy (13-15 mg/kg) from June 1, 2014, to December 31, 2021. The criterion for UDCA non-response was defined as an alkaline phosphatase (ALP) level exceeding 1.67 times the upper limit of normal (ULN) after 12 months of UDCA therapy. Logistic regression analysis was utilized to examine the relationship between baseline PNI and response to UDCA. The stableness of the findings was assessed through both unadjusted and adjusted models.
resultsThe study included 241 patients with PBC (mean age 55.80 ± 11.694 years; 210 (87.1%) females). During the 12-month clinical follow-up, 83 patients exhibited non-responsiveness to UDCA, corresponding to a non-response rate of 34.44%. Univariate binary logistic regression analysis indicated that factors such as alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bile acid, total cholesterol, neutrophils, and PNI were associated with UDCA non-responsiveness (p < 0.05). Multivariate regression analysis showed that lower baseline PNI was associated with UDCA non-response (odds ratio [OR]: 0.882, 95% confidence interval [CI]: 0.825-0.943, p < 0.001). PNI showed modest discriminatory ability for UDCA non-response, with an AUROC of 0.664 in the overall cohort and 0.676 in non-cirrhotic patients. Based on the Youden index, the optimal PNI cut-off value was 49.03.
conclusionsLower baseline PNI was associated with inadequate biochemical response to UDCA in patients with PBC and may serve as a supportive risk stratification marker. However, its modest discriminatory performance and retrospective design limit its standalone clinical application. Further prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.